Business Context and Reporting Period
This Form 8-K filing by LeMaitre Vascular, Inc. (LMAT) reports corporate governance changes dated April 8, 2026. The filing addresses the departure of a director and the subsequent restructuring of the Board of Directors ahead of the 2026 Annual Meeting of Stockholders scheduled for June 2, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Director Departure: Bridget Ross notified the Board of her intent not to stand for re-election as a Class II director. Her term will expire at the 2026 Annual Meeting.
- Director Nomination and Resignation: David B. Roberts was nominated to replace Ms. Ross as a Class II director. To facilitate this, Mr. Roberts intends to resign as a Class I director upon his election as a Class II director.
- Board Size Reduction: The Board has reduced its size from eight to seven members, effective immediately upon Ms. Ross's departure.
- Board Composition: Following these changes, the Board will consist of seven members: two Class I, two Class II, and three Class III directors.
Guidance, Outlook, and Risks
The filing states that Ms. Ross's decision not to seek re-election and Mr. Roberts's conditional resignation are not related to any disagreement with the Company regarding operations, policies, or practices. The document includes standard forward-looking statement disclaimers, noting that actual results may differ from expectations due to risks detailed in the Company's most recent Form 10-K.
Key Facts for Investor Verification
- Confirm the final composition of the Board of Directors following the June 2, 2026, Annual Meeting.
- Verify that the reduction in Board size from eight to seven members is reflected in subsequent proxy materials.
- Review the Company's most recent Form 10-K for detailed risk factors referenced in this filing.